VIVUS, Inc. (NASDAQ:VVUS)

CAPS Rating: 2 out of 5

A pharmaceutical company dedicated to the development and commercialization of therapeutic products using patented proprietary formulations and novel delivery systems and by seeking new indications for previously approved pharmaceutical products.

Results 1 - 20 of 84 : 1 2 3 4 5 Next »

Recs

0
Member Avatar pchop12316 (63.37) Submitted: 5/3/2016 12:00:32 PM : Underperform Start Price: $1.58 VVUS Score: +12.56

price sensitive here and may drop substantially

Recs

0
Member Avatar NHWeston102 (< 20) Submitted: 4/5/2016 8:58:57 AM : Underperform Start Price: $1.56 VVUS Score: +12.04

Another once-promising biotech that failed to monetize its research, experienced delays in its approvals, and turned out not to be the innovator investors thought. Sad. I made money on them once.

Recs

0
Member Avatar zzlangerhans (99.79) Submitted: 4/4/2016 4:57:03 PM : Underperform Start Price: $1.41 VVUS Score: +2.82

Vivus is enjoying an awesome rebound from the February low of 0.92, but when I look at the stock all I see is bankruptcy chow. Cash of 241M is counteracted by 236M in debt, and the company is still losing double digit millions per quarter. So what's the deal with 150M in enterprise value? I don't see Qsymia and Stendra making Vivus cash flow positive, so that just leaves a Dendreon/Savient/Mannkind-like descent into unserviceable debt. Those companies enjoyed their brief resurgences as well, but the end wasn't pretty (I'm projecting for Mannkind). With all the biotechs that are still trading cheaply after the winter massacre, why bet on a continued run for this doomed stock?

Recs

0
Member Avatar clangmead (48.53) Submitted: 2/11/2016 9:37:33 AM : Outperform Start Price: $0.97 VVUS Score: +29.32

mtsi

Recs

1
Member Avatar Hendrickson71 (< 20) Submitted: 9/18/2015 4:46:13 PM : Outperform Start Price: $1.73 VVUS Score: -24.90

Something big will happen on Monday..... just don't know if it is good or bad but I'm holding

Recs

0
Member Avatar DeathStock (99.30) Submitted: 9/11/2015 11:12:45 AM : Outperform Start Price: $2.02 VVUS Score: -37.15

Agree with superstar, a big slingshot launch to the upside should be expected from here. I thought I got this pick in at a lower price though ($1.88ish).

Recs

1
Member Avatar superstar (99.76) Submitted: 9/11/2015 10:17:12 AM : Outperform Start Price: $1.98 VVUS Score: -35.64

Big upside coming

Recs

0
Member Avatar s2dbaker (91.59) Submitted: 10/16/2013 11:04:44 PM : Outperform Start Price: $9.66 VVUS Score: -105.27

A pill that help prevent type II diabetes and promotes weight loss. This is a winner.

Recs

0
Member Avatar LIFESAVA1 (< 20) Submitted: 4/19/2013 5:31:47 PM : Outperform Start Price: $11.88 VVUS Score: -120.05

VVUS HAS A GREAT WEIGHT LOSS PRODUCT

Recs

1
Member Avatar TheStockDoctor (< 20) Submitted: 3/3/2013 9:37:23 PM : Underperform Start Price: $10.24 VVUS Score: +121.69

Qsymia was a total flop at initial release, and that is without any competition. As soon as Belviq hits the shelves, Qsymia sales will drop substantially.

Recs

0
Member Avatar SmartEquity (56.80) Submitted: 1/21/2013 9:09:52 AM : Outperform Start Price: $13.34 VVUS Score: -127.93

I believe the scrips will pick up as distribution is improved. The obesity patients will choose a riskier Qsymia over a safer less effective Belviq.

Recs

0
Member Avatar clymerjones (51.90) Submitted: 10/17/2012 11:09:13 AM : Outperform Start Price: $22.25 VVUS Score: -134.23

Strong product/development initiatives will out class the S&P

Recs

0
Member Avatar dausama (87.86) Submitted: 9/23/2012 9:54:13 AM : Underperform Start Price: $20.62 VVUS Score: +134.60

no EU approval

Recs

0
Member Avatar donodonuts (40.33) Submitted: 8/9/2012 7:16:43 AM : Outperform Start Price: $21.77 VVUS Score: -139.85

Sold it at like 8, oops. But their stuff hasn't hit the market yet, I'd like to think it will go up more when they have actual sales.

Recs

0
Member Avatar rick3000 (< 20) Submitted: 7/17/2012 5:16:39 PM : Underperform Start Price: $30.33 VVUS Score: +146.19

Inflated by ARNA approval, will crash to actual value if rejected or with restrictive label. Management has a black eye from handling of FDA announcement.

Recs

0
Member Avatar ravens9111 (< 20) Submitted: 7/16/2012 11:26:58 AM : Underperform Start Price: $27.97 VVUS Score: +146.26

Betting against this stock's FDA decision tomorrow. Price is most likely already priced in for approval. I expect a sell the news event even if approval is granted. However, if rejected, this stock will go to low teens to high single digits.

Recs

0
Member Avatar HIGHG33K (80.44) Submitted: 7/13/2012 8:39:49 PM : Outperform Start Price: $27.55 VVUS Score: -146.40

FDA approval is inevitable.

Recs

0
Member Avatar natemwilson (40.89) Submitted: 6/28/2012 12:08:47 PM : Underperform Start Price: $28.54 VVUS Score: +150.66

Too many adverse side effects to be approved.

Recs

0
Member Avatar nobleartjim (< 20) Submitted: 6/23/2012 9:48:19 AM : Outperform Start Price: $26.34 VVUS Score: -150.06

Recent developing products now undergoing FDA tests appear favorable

Recs

0
Member Avatar BACnumber1 (< 20) Submitted: 6/12/2012 12:13:40 PM : Outperform Start Price: $24.75 VVUS Score: -149.61

Fine stock, but I'm way bigger on ARNA

Results 1 - 20 of 84 : 1 2 3 4 5 Next »

Featured Broker Partners